New to peptides? Start with the foundations ->
What it does - plain English
PT-141 (also called Bremelanotide) is a synthetic peptide that activates melanocortin receptors - a family of receptors in the body involved in arousal, appetite, and skin pigmentation. Unlike Viagra (which works on blood flow to the genitals), PT-141 works on the central nervous system. It acts in the brain to increase desire, not just physical response.
The FDA approved it as Vyleesi in 2019 for premenopausal women with HSDD - hypoactive sexual desire disorder, the clinical name for low libido that causes meaningful distress. That is a real diagnosis with real trial data behind it.
It is used off-label by men and post-menopausal women, though those uses are not FDA-evaluated. The data there is thinner, and mostly community-sourced.
Status
A-tier within its FDA-approved indication. The Phase 3 RECONNECT and BLOOM trials were the basis for approval. That is a real regulatory bar: large randomized trials, peer-reviewed results, safety review. Not many peptides on this site can say that.
Off-label use in men is community-driven. The drug works through the same receptor pathway in both sexes, but there are no large controlled human trials for that use. The evidence is thinner and the dosing is mostly anecdotal.
The drug has notable side effects. Nausea hit more than 40% of participants in the approval trials. Facial flushing and headache are also common. Most reactions resolve within a few hours, but it is not a subtle compound - you will know if your body reacts.
Legal status
PT-141 is FDA-approved as Vyleesi (autoinjector form) for premenopausal HSDD. That means it went through the full drug approval process - it is not a research chemical for that indication.
Off-label prescriptions for other uses are legal in the United States. Doctors can legally prescribe any approved drug for any use they judge clinically appropriate. Insurance usually will not cover off-label use, so expect to pay out of pocket.
Research-grade PT-141 is also sold by peptide vendors as research material - the same gray zone as BPC-157. That is not the regulated product. Purity and dosing are on you.
Where to source
Two paths exist. The first is prescription Vyleesi through a gynecologist or a telehealth provider that works with women's health. For the on-label indication (premenopausal HSDD), some insurance plans cover it. This is the regulated version with known dosing, a known manufacturing process, and a COA (Certificate of Analysis - the lab report confirming purity and concentration) baked into the pharmaceutical supply chain.
The second path is research peptide vendors. These sell PT-141 as research material - not for human use by their label, though that is how most buyers use it. Always ask for a COA before buying. No COA, no buy. Period. Dosing decisions are entirely on the buyer and carry real risk without medical guidance.
Subscribe below to get vendor reviews and price snapshots in the weekly dispatch.
Two studies worth reading
Premenopausal HSDD approval trials
Kingsberg, S. et al., Obstetrics & Gynecology
Combined results from the RECONNECT studies. 1,247 premenopausal women with HSDD. Statistically significant improvements in desire scores and reduced distress about sexual function. The trials that won FDA approval.
Mechanism of action review
Pfaus, J. et al., European Journal of Pharmacology
Mechanistic paper covering the MC4R-receptor activation pathway and central nervous system effects. Useful for understanding why PT-141 acts differently from PDE5 inhibitors like Viagra - it is a brain-level signal, not a vascular one.
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.
Last reviewed · 2026·05·04 · Status reviewed weekly